Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

4th approved indication for toripalimab SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the National Medical Products Administration (NMPA) of China has approved its supplemental New Drug Application (sNDA) for toripalimab in combination with cisplatin and gemcitabine as the first-line treatment […]

Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of its Board of Directors

SAN DIEGO and BASEL, Switzerland, Nov. 29, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Jacob Chacko, M.D., as Chair of its Board of Directors. Dr. Chacko currently serves as President, CEO and member of the Board […]